Profile data is unavailable for this security.
About the company
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
- Revenue in AUD (TTM)21.87bn
- Net income in AUD3.81bn
- Incorporated1991
- Employees32.07k
- LocationCSL Ltd45 Poplar Road,, ParkvilleMELBOURNE 3052AustraliaAUS
- Phone+61 39389-1911
- Fax+61 39389-1434
- Websitehttps://www.csl.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka Holdings Co Ltd | 19.51bn | 1.18bn | 34.28bn | 34.39k | 28.37 | 1.44 | 15.88 | 1.76 | 224.09 | 224.09 | 3,719.71 | 4,410.81 | 0.6246 | 2.58 | 4.50 | 58,699,780.00 | 3.88 | 4.80 | 4.85 | 5.88 | 69.72 | 68.21 | 6.22 | 8.36 | 1.61 | -- | 0.0808 | 42.16 | 16.14 | 9.33 | -9.18 | 8.07 | 9.27 | 1.92 |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 4.93bn | 936.17m | 58.88bn | 19.61k | 62.76 | 6.63 | -- | 11.95 | 0.6963 | 0.6963 | 3.66 | 6.59 | 0.5263 | 1.59 | 4.43 | 1,189,383.00 | 9.96 | 13.68 | 10.86 | 15.20 | 83.56 | 85.87 | 18.91 | 20.01 | 8.50 | -- | 0.0066 | 23.77 | 7.26 | 5.55 | 10.14 | 1.14 | 22.90 | 9.45 |
| Takeda Pharmaceutical Co Ltd | 40.30bn | 1.72bn | 63.25bn | 49.10k | 36.66 | 0.9623 | 7.43 | 1.57 | 112.79 | 112.79 | 2,647.34 | 4,297.22 | 0.3007 | 1.29 | 5.86 | 84,917,990.00 | 1.29 | 1.79 | 1.54 | 2.14 | 67.52 | 68.57 | 4.28 | 6.81 | 0.5518 | 2.83 | 0.4089 | 121.86 | 12.85 | 17.87 | 37.80 | 11.15 | 37.64 | 0.00 |
| Sun Pharmaceutical Industries Ltd | 8.71bn | 1.63bn | 65.42bn | 41.00k | 40.03 | -- | 30.79 | 7.51 | 37.11 | 37.11 | 197.73 | -- | -- | -- | -- | 11,571,860.00 | -- | 6.31 | -- | 9.02 | 77.80 | 70.08 | 18.97 | 12.17 | -- | 52.77 | -- | 39.54 | 13.53 | 10.62 | 158.91 | 29.24 | 1.24 | 41.88 |
| Chugai Pharmaceutical Co Ltd | 10.01bn | 3.15bn | 83.60bn | 7.60k | 25.97 | 5.16 | -- | 8.35 | 198.34 | 198.34 | 629.62 | 997.97 | 0.5647 | 1.21 | 3.45 | 136,254,000.00 | 17.79 | 19.29 | 20.95 | 23.91 | 67.67 | 63.55 | 31.50 | 28.39 | 4.37 | -- | -- | 40.14 | -11.78 | 13.90 | -13.08 | 28.61 | -0.8947 | 27.23 |
| Daiichi Sankyo Co Ltd | 14.53bn | 1.80bn | 89.00bn | 17.44k | 48.77 | 5.72 | 36.56 | 6.12 | 96.97 | 96.97 | 783.61 | 827.32 | 0.5306 | 1.27 | 3.69 | 86,232,860.00 | 6.59 | 4.43 | 8.11 | 5.40 | 72.28 | 66.08 | 12.41 | 9.13 | 2.84 | -- | 0.0603 | 53.12 | 22.36 | 5.89 | 62.63 | 13.68 | 12.13 | 5.15 |
| CSL Ltd | 21.87bn | 3.81bn | 134.56bn | 32.07k | 35.38 | 5.08 | 25.65 | 6.15 | 7.87 | 7.87 | 45.21 | 54.83 | 0.3898 | 1.29 | 4.38 | 681,898.40 | 6.94 | 11.12 | 8.48 | 13.77 | 51.57 | 54.80 | 17.80 | 21.00 | 0.9708 | 7.79 | 0.3872 | 45.86 | 26.02 | 10.95 | -2.69 | 4.88 | 11.26 | 7.44 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 17.14m | 3.55% |
| State Street Global Advisors, Australia, Ltd.as of 15 Mar 2024 | 15.35m | 3.18% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 8.71m | 1.80% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 7.91m | 1.64% |
| Vanguard Investments Australia Ltd.as of 29 Feb 2024 | 7.25m | 1.50% |
| State Street Global Advisors Trust Co.as of 15 Mar 2024 | 5.35m | 1.11% |
| Colonial First State Investments Ltd.as of 31 Jul 2023 | 4.73m | 0.98% |
| Geode Capital Management LLCas of 11 Apr 2024 | 3.68m | 0.76% |
| Commonwealth Superannuation Corp. (Investment Management)as of 31 Jul 2023 | 3.28m | 0.68% |
| First Sentier Investors (Hong Kong) Ltd.as of 31 Dec 2023 | 2.84m | 0.59% |
